Granules Pharmaceuticals Inc. recalls Metoprolol Succinate…
Granules Pharmaceuticals Inc. recalls Metoprolol Succinate Extended-Release Tablets
- Published
- 9 Jul 2025
- Units affected
- 27,648 100-count Bottles; 5,376 500-count Bottles
- Agency
- FDA
- Country
- United States
The hazard
Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH) long-term.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Metoprolol Succinate Extended-Release Tablets, USP, 25 mg, Packaged in a) 100-count bottle, NDC 70010-780-01; b) 500-count bottle, NDC 70010-780-05; Rx only, Manufactured by: Granules India Limited, Hyderadab-500 081, India, Manufactured for: Granules Pharmaceuticals Inc., Chantilly, VA 20151,
- Brand / company
- Granules Pharmaceuticals Inc.
- Codes / lots
- Lot # a)1400008A, Exp Date: 12/31/2025; b) 1400008B, Exp Date: 12/31/2025
- Distribution
- Nationwide in the USA.
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 9 Jul 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.